$IDXX

IDEXX Laboratories (IDXX) reported $4.6B revenue in the past year, up 12.8%, with net profit at 25%. Management raised 2026 guidance to $4.7B-$4.75B. Analysts' price target is $698.92, implying 38% upside. IDXX trades at 35.5x trailing P/E, higher than peers, reflecting expectations of sustained earnings growth. Risks include slower veterinary demand and weaker adoption of new diagnostics.

Goldman Sachs identifies long-term trends like AI, e-commerce, and pet ownership as drivers for stock performance. The firm highlights Idexx Laboratories (IDXX) and Zeta Global (ZETA) as stocks to buy, citing recurring revenue and growth potential. IDXX reported $1.22B in Q2 revenue, up 10% YoY, with a $740 price target. ZETA saw $443M in Q2 revenue, up 43% YoY, with a positive earnings beat.

JPMorgan reduced its price target for IDEXX Laboratories to $750 from $775. The company's stock is currently trading at $547.18, with a 5-day change of +3.43% and a year-to-date change of +6.63%. KeyBanc initiated coverage with a Sector Weight rating.

BofA upgraded Salesforce (CRM) to Buy with a $285 target, citing enterprise platform resilience. Raymond James upgraded Humana (HUM) to Outperform with a $520 target, noting Medicare Advantage growth. T-Mobile (TMUS) also upgraded to Outperform with a $170 target. Truist upgraded First Solar (FSLR) to Buy with a $270 target. JPMorgan upgraded Biogen (BIIB) to Overweight with a $300 target. Wells Fargo double-downgraded Adobe (ADBE) to Underweight with a $225 target.

KeyBanc initiated coverage on Idexx Laboratories (IDXX) with a Sector Weight rating, citing strong financial health but expecting soft U.S. veterinary visits to impact valuation. The stock trades at $518 with a P/E ratio of 36.44. IDEXX reported Q2 earnings of $4.27 per share on revenue of $1.22 billion, exceeding estimates, and raised its full-year guidance. Stifel reiterated a Buy rating with a $675 price target.

IDEXX Laboratories reported increased pet population and medicalization, driving diagnostic demand. The company highlighted growth in its inVue Dx and MultiQ Dx platforms, with the former already meeting revenue targets. IDEXX Cancer Dx is expanding, driving reference lab growth. The company reaffirmed its long-term growth targets and expects mid-range revenue and margin expansion in the second half. IDEXX is investing in commercial expansions and shareholder returns.

IDEXX Laboratories (IDXX) acquired CoVetAI, a veterinary software company, to enhance its diagnostic services. The tool integrates with IDEXX's existing systems and aims to increase diagnostic test usage. IDEXX reported Q2 revenue growth of 10% and 11% in recurring diagnostics, with over 1,600 new analyzers placed. The deal terms were not disclosed, and the long-term impact on earnings is uncertain. IDEXX's forward P/E is 30.86 as of September 18.

IDEXX Laboratories (IDXX) acquired CoVetAI, an AI-driven veterinary workflow software provider. The deal expands IDEXX's offerings, integrating CoVet's tools. IDXX shares closed at $510.73 on Tuesday. Financial terms were not disclosed.

Kingsley Lawrence D sold 2,203 shares of IDEXX LABORATORIES INC /DE (IDXX) at $532.08 ($1.17M total) on 2026-09-04.

IDEXX Laboratories (NASDAQ: IDXX) reported Q3 earnings that exceeded EPS and revenue expectations, raising full-year guidance. The stock rose 15% following the announcement.